187 related articles for article (PubMed ID: 33431153)
1. What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model.
Rafferty ERS; McDonald W; Osgood ND; Doroshenko A; Farag M
Value Health; 2021 Jan; 24(1):50-60. PubMed ID: 33431153
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
[TBL] [Abstract][Full Text] [Related]
3. Seeking the optimal schedule for chickenpox vaccination in Canada: Using an agent-based model to explore the impact of dose timing, coverage and waning of immunity on disease outcomes.
Rafferty ERS; McDonald W; Osgood ND; Qian W; Doroshenko A
Vaccine; 2020 Jan; 38(3):521-529. PubMed ID: 31735499
[TBL] [Abstract][Full Text] [Related]
4. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
Bilcke J; van Hoek AJ; Beutels P
Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
Ahern S; Browne J; Murphy A; Teljeur C; Ryan M
Vaccine; 2024 May; 42(14):3321-3332. PubMed ID: 38609807
[TBL] [Abstract][Full Text] [Related]
7. Varicella vaccination in Italy : an economic evaluation of different scenarios.
Coudeville L; Brunot A; Giaquinto C; Lucioni C; Dervaux B
Pharmacoeconomics; 2004; 22(13):839-55. PubMed ID: 15329030
[TBL] [Abstract][Full Text] [Related]
8. Varicella vaccination in England and Wales: cost-utility analysis.
Brisson M; Edmunds WJ
Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
[TBL] [Abstract][Full Text] [Related]
9. Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data.
Goldman GS; King PG
Hum Exp Toxicol; 2014 Aug; 33(8):886-93. PubMed ID: 24275643
[TBL] [Abstract][Full Text] [Related]
10. The economic value of childhood varicella vaccination in France and Germany.
Coudeville L; Brunot A; Szucs TD; Dervaux B
Value Health; 2005; 8(3):209-22. PubMed ID: 15877593
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.
Bonanni P; Boccalini S; Bechini A; Banz K
Vaccine; 2008 Oct; 26(44):5619-26. PubMed ID: 18723062
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of varicella vaccination in Canada.
Brisson M; Edmunds WJ
Vaccine; 2002 Jan; 20(7-8):1113-25. PubMed ID: 11803072
[TBL] [Abstract][Full Text] [Related]
13. Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.
Holl K; Sauboin C; Amodio E; Bonanni P; Gabutti G
BMC Public Health; 2016 Oct; 16(1):1103. PubMed ID: 27769206
[TBL] [Abstract][Full Text] [Related]
14. Health disparities in chickenpox or shingles in Alberta?
Russell ML; Schopflocher DP; Svenson LW
Can J Public Health; 2008; 99(1):41-5. PubMed ID: 18435390
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.
Valentim J; Sartori AM; de Soárez PC; Amaku M; Azevedo RS; Novaes HM
Vaccine; 2008 Nov; 26(49):6281-91. PubMed ID: 18674582
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.
Wolfson LJ; Daniels VJ; Pillsbury M; Kurugöl Z; Yardimci C; Kyle J; Dinleyici EC
PLoS One; 2019; 14(8):e0220921. PubMed ID: 31408505
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
[TBL] [Abstract][Full Text] [Related]
18. Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.
van Lier A; Lugnér A; Opstelten W; Jochemsen P; Wallinga J; Schellevis F; Sanders E; de Melker H; van Boven M
EBioMedicine; 2015 Oct; 2(10):1494-9. PubMed ID: 26629544
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of varicella vaccination programs: an update of the literature.
Rozenbaum MH; van Hoek AJ; Vegter S; Postma MJ
Expert Rev Vaccines; 2008 Aug; 7(6):753-82. PubMed ID: 18665775
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
